Search

Imugene

Investors turn to innovation

FEATURE: Biotech and IT companies are enjoying renewed investor interest, but these innovative businesses are facing a changing capital raising market featuring less government support and, in Perth, a drastic shift in the venture capital sector.

Market chemistry grows biotech deals

SPECIAL REPORT: The biotech sector came to life in 2013 but pricing was critical to the success or failure of capital raisings.

Imugene's porcine patent protected until 2021 in USA

Perth biotechnology company Imugene Ltd has received notice of grant for patent protection for its Porcine Adenoviral Delivery Vector technology in the United States of America, the company has announced.

Arafura Resources, Imugene secure $4.2m in R&D grants

Arafura Resources Ltd has been awarded a $3.3 million federal government grant for its NT rare earths-uranium project while biotechnology company Imugene Ltd has secured an $880,000 grant to produce and test bird flu vaccines on chickens.

Imugene wins US patent case

WA-based biotechnology company Imugene Ltd has won exclusive distribution rights for its porcine adenoviral vector delivery system, after success in a hearing administered by the US patent office.

Regulatory tick for Imugene

Biotechnology company Imugene said it has achieved “one of its biggest regulatory milestones” with a licence for the limited release of its poultry productivity enhancer (PPE).

Imugene finalises placement

ANIMAL vaccine developer Imugene has finalised a $5 million share placement it announced on November 23.The funds were raised from institutional and sophisticated investors and will be used to speed u

Imugene Ltd

24-Nov-04Portfolio Partners Ltd became a substantial shareholder with a relevant interest of 10,649,647 ordinary shares (9.83%).

Imugene gains Japanese patent

VETERINARY health company Imugene has been granted a key patent in Japan for the product that is the basis of its poultry vaccines.Called the Fowl Adenoviral Delivery Vector, the product is a componen

Imugene targets Chemeq’s market

PHARMACEUTICAL company Imugene has become a direct competitor to Chemeq after licensing a new technology developed at the University of Adelaide.